Switch theme
Sign up to access all valuation multiples
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
1973
n/a
LTM Revenue $97.4M
LTM EBITDA $3.0M
$953M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hanall Biopharma has a last 12-month revenue of $97.4M and a last 12-month EBITDA of $3.0M.
In the most recent fiscal year, Hanall Biopharma achieved revenue of $94.7M and an EBITDA of $2.0M.
Hanall Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hanall Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $91.9M | $94.7M | XXX | XXX | XXX |
| Gross Profit | $42.2M | $51.2M | XXX | XXX | XXX |
| Gross Margin | 46% | 54% | XXX | XXX | XXX |
| EBITDA | $4.4M | $2.0M | XXX | XXX | XXX |
| EBITDA Margin | 5% | 2% | XXX | XXX | XXX |
| Net Profit | $0.2M | $2.4M | XXX | XXX | XXX |
| Net Margin | 0% | 3% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hanall Biopharma's stock price is KRW 27950 (or $19).
Hanall Biopharma has current market cap of KRW 1.42T (or $968M), and EV of KRW 1.40T (or $953M).
See Hanall Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $953M | $968M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hanall Biopharma has market cap of $968M and EV of $953M.
Hanall Biopharma's trades at 9.8x LTM EV/Revenue multiple, and 316.0x LTM EBITDA.
Analysts estimate Hanall Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hanall Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $953M | XXX | XXX | XXX |
| EV/Revenue | 10.1x | XXX | XXX | XXX |
| EV/EBITDA | 464.7x | XXX | XXX | XXX |
| P/E | -787.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -102.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHanall Biopharma's NTM/LTM revenue growth is 11%
Hanall Biopharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hanall Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hanall Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hanall Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -54% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 13% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hanall Biopharma acquired XXX companies to date.
Last acquisition by Hanall Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Hanall Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hanall Biopharma founded? | Hanall Biopharma was founded in 1973. |
| Where is Hanall Biopharma headquartered? | Hanall Biopharma is headquartered in South Korea. |
| Who is the CEO of Hanall Biopharma? | Hanall Biopharma's CEO is Mr. Seung-guk Park. |
| Is Hanall Biopharma publicy listed? | Yes, Hanall Biopharma is a public company listed on KRX. |
| What is the stock symbol of Hanall Biopharma? | Hanall Biopharma trades under 009420 ticker. |
| When did Hanall Biopharma go public? | Hanall Biopharma went public in 1989. |
| Who are competitors of Hanall Biopharma? | Similar companies to Hanall Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hanall Biopharma? | Hanall Biopharma's current market cap is $968M |
| What is the current revenue of Hanall Biopharma? | Hanall Biopharma's last 12-month revenue is $97.4M. |
| What is the current EBITDA of Hanall Biopharma? | Hanall Biopharma's last 12-month EBITDA is $3.0M. |
| What is the current EV/Revenue multiple of Hanall Biopharma? | Current revenue multiple of Hanall Biopharma is 9.8x. |
| What is the current EV/EBITDA multiple of Hanall Biopharma? | Current EBITDA multiple of Hanall Biopharma is 316.0x. |
| What is the current revenue growth of Hanall Biopharma? | Hanall Biopharma revenue growth between 2023 and 2024 was 3%. |
| Is Hanall Biopharma profitable? | Yes, Hanall Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
